Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Ramsay Healthcare Placement - Past Deals Have Done Well, Missed Revenue Will Be Back

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Ramsay Health Care / Equity Capital Markets

Ramsay Health Care's largest shareholder, Paul Ramsay Foundation, is selling AUD 1.3 billion block after market close today. In this insight, we would like to discuss our thoughts on the deal. The company is a decent blue-chip healthcare stock operating the largest private hospital chains in Australia, France and Scandinavian. It offers undemanding valuation compared to other Australia listed healthcare peers with a track record of growing its dividend payout. Hence we believe the deal will attract long-only participation. Despite an average positive one month return, the recent deal did not do well and the deal scores slightly negative in our ECM Framework. We would bid the deal at the low end.

Ramsay Health Care's largest shareholder, Paul Ramsay Foundation, is selling AUD 1.3 billion block after market close today. In this insight, we would like to discuss our thoughts on the deal. The company is a decent blue-chip healthcare stock operating the largest private hospital chains in Australia, France and Scandinavian. It offers undemanding valuation compared to other Australia listed healthcare peers with a track record of growing its dividend payout. Hence we believe the deal will attract long-only participation. Despite an average positive one month return, the recent deal did not do well and the deal scores slightly negative in our ECM Framework. We would bid the deal at the low end.

Ramsay Health Care A$1.3bn Placement - A Decent Stock but Past Performance Weighs